Publication: The effects of estrone, estradiol and estriol on platelet aggregation induced by adrenaline and adenosine diphosphate
Issued Date
2006-11-01
Resource Type
ISSN
13691635
09537104
09537104
Other identifier(s)
2-s2.0-33750503604
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Platelets. Vol.17, No.7 (2006), 441-447
Suggested Citation
Pravit Akarasereenont, Pinpat Tripatara, Sirikul Chotewuttakorn, Titchaporn Palo, Athiwat Thaworn The effects of estrone, estradiol and estriol on platelet aggregation induced by adrenaline and adenosine diphosphate. Platelets. Vol.17, No.7 (2006), 441-447. doi:10.1080/09537100600745302 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/22953
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The effects of estrone, estradiol and estriol on platelet aggregation induced by adrenaline and adenosine diphosphate
Other Contributor(s)
Abstract
The impact of estrogens on the cardiovascular system and their ability to regulate platelet functions remains controversial. Changes in platelet functions could contribute to thrombotic risk associated with estrogen treatments. Here, we investigated the effects of various forms of estrogen, including estrone (E1), estradiol (E2) and estriol (E3), on platelet aggregation induced by standard agonists (adrenaline and adenosine diphosphate). Platelet-rich plasma (PRP) was prepared from citrated blood donated by 25 normal volunteers. The study on platelet aggregation was carried out in 96-well flat-bottom microtitre plates and assessed using a microplate reader. For studying the effects of each estrogen, PRP was preincubated with 1, 10 and 100 nM of E1, E2 and E3 at 37°C for 20 min, and then coincubated with normal saline (control untreated PRP), adrenaline (ADR) or adenosine diphosphate (ADP) in the microplate. Platelet aggregation was then measured every minute for 8 min. None of the estrogens (E1, E2 and E3) affected platelet aggregation in untreated PRP. Interestingly, only E1 and E3 can synergize the increased platelet aggregation by either ADR or ADP, while the effects of E2 on the increased platelet aggregation by either ADR or ADP depended on internal factors such as endogenous estradiol and platelet aggregated state. Thus, for the rational use of these internal factors for estrogen use, especially E2, in clinical applications, such as hormone replacement therapy, may need evaluation of thrombotic risk. © 2006 Informa UK Ltd.